
## **Cindy Sander**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4376176/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients. Journal of Experimental Medicine, 2010, 207, 2175-2186.	4.2	1,118
2	TIGIT and PD-1 impair tumor antigen–specific CD8+ T cells in melanoma patients. Journal of Clinical Investigation, 2015, 125, 2046-2058.	3.9	603
3	Immune Monitoring of the Circulation and the Tumor Microenvironment in Patients with Regionally Advanced Melanoma Receiving Neoadjuvant Ipilimumab. PLoS ONE, 2014, 9, e87705.	1.1	261
4	Tumor cell oxidative metabolism as a barrier to PD-1 blockade immunotherapy in melanoma. JCI Insight, 2019, 4, .	2.3	148
5	CD226 opposes TIGIT to disrupt Tregs in melanoma. JCI Insight, 2018, 3, .	2.3	137
6	Immunization With Analog Peptide in Combination With CpG and Montanide Expands Tumor Antigen-specific CD8+ T Cells in Melanoma Patients. Journal of Immunotherapy, 2008, 31, 781-791.	1.2	108
7	IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma. Clinical Cancer Research, 2020, 26, 5520-5533.	3.2	88
8	Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma. Journal of Clinical Oncology, 2018, 36, 3450-3458.	0.8	55
9	The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells <i>in vitro</i> and <i>in vivo</i> . Oncotarget, 2017, 8, 16367-16386.	0.8	55
10	Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, Gα <sub>q</sub> and Gα <sub>11</sub> and kill uveal melanoma cells. Cancer Biology and Therapy, 2019, 20, 700-710.	1.5	37
11	The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib. Cancer Biology and Therapy, 2018, 19, 132-137.	1.5	32
12	Expression profiles of immune-related genes are associated with neoadjuvant ipilimumab clinical benefit. Oncolmmunology, 2017, 6, e1231291.	2.1	29
13	Tim-3 mediates T cell trogocytosis to limit antitumor immunity. Journal of Clinical Investigation, 2022, 132, .	3.9	25
14	Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma. Clinical Cancer Research, 2021, 27, 4195-4204.	3.2	18
15	Predicting Metastasis in Melanoma by Enumerating Circulating Tumor Cells Using Photoacoustic Flow Cytometry. Lasers in Surgery and Medicine, 2021, 53, 578-586.	1.1	10